Application of gambogicacid in preparing medication for restraining angiogenesis

A technique for angiogenesis and tumor angiogenesis, which can be used in drug combinations, antipyretics, antitumor drugs, etc., and can solve the problem of lack of gambogic acid.

Inactive Publication Date: 2007-10-10
CHINA PHARM UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is currently no report of gambogic acid as an angiogenesis inhibitor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of gambogicacid in preparing medication for restraining angiogenesis
  • Application of gambogicacid in preparing medication for restraining angiogenesis
  • Application of gambogicacid in preparing medication for restraining angiogenesis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1: Gambogic acid inhibits angiogenesis of chicken embryo allantoic membrane.

[0021] Purpose and principle: In the early stage of angiogenesis of chicken embryo chorioallantoic membrane, the body’s immune system has not yet been fully established, and there is almost no rejection reaction to various foreign bodies. The drug-containing carrier is placed on its surface, and the effect of the drug on angiogenesis can be observed. influences. Because of its sensitivity to anti-angiogenic drugs, it is still considered an ideal drug screening model.

[0022] Method: The fertilized chicken embryos were placed in the incubator for 9 days (the air cell side is up). Then wipe the chicken embryo with alcohol and let it stand for 15 minutes, draw a 2×2cm window opening position above the chicken embryo, grind and cut the window with scissors, blow off the grinding dust on the eggshell, and remove the window. Then use iris scissors to cut the shell membrane, exposing the ...

Embodiment 2

[0024] Example 2: Gambogic acid inhibits angiogenesis of rat arterial rings cultured in vitro.

[0025] Purpose and principle: Rat aortic rings were embedded in a gel matrix to observe endothelial cells budding from the intima and forming capillary-like structures.

[0026] Methods: One male Wistar rat weighing 100-120 g was sacrificed by dislocation, the thoracic aorta was removed, the peripheral connective tissue and adipose tissue were removed, the arterial ring was cut into a 1 mm long ring, and rinsed with M199 serum-free culture medium. The rat aortic segment was embedded in fibrin glue in a 24-well plate, and cultured in vitro with M199 culture solution (control group, without gambogic acid) and culture solution containing different concentrations of gambogic acid. Change the medium once every 3 days.

[0027] RESULTS AND EVALUATION: Endothelial cells grew outward from the arterial incision, forming a branched microvessel-like structure. After 7 days, the formation of...

Embodiment 3

[0028] Example 3: Gambogic acid inhibits migration of endothelial cells.

[0029] Purpose and principle: The endothelial cell migration experiment was carried out in a transwell cell culture chamber. The polycarbonate filter membrane with a pore size of 8 μm separates the chamber into upper and lower layers. Under the stimulation of growth factors, endothelial cells pass through the 8 μm filter pores through amoeba movement and attach to the back of the filter membrane. This model can be used to evaluate the effect of drugs on the migration ability of endothelial cells.

[0030] Method: Endothelial cells were treated with 1640 medium containing different concentrations of gambogic acid for 30 minutes, and then 2.5×10 5 400 μl of cell suspension of each / ml HUVEC was added to the upper chamber, and 600 μl of 1640 culture medium containing stimulatory factors and different concentrations were added to the lower chamber, and placed in 5% CO 2 Incubate in an incubator at 37°C fo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An application of garcinolic acid in preparing the medicines for suppressing the angiogenesis of tumor, arthritis, retinopathy, angioma and psoriasis and in turn treating them is disclosed.

Description

technical field [0001] The invention relates to a new application of gambogic acid, in particular to the application of gambogic acid in the preparation of drugs for inhibiting angiogenesis. Background technique: [0002] Angiogenesis refers to the formation of new capillaries from pre-existing capillaries and postcapillary veins. Blood vessels are an important way to transport oxygen, nutrients and metabolites, and it is difficult for tissues or organs to survive without vascular support, so angiogenesis occurs along with the formation of organs and tissues in the body. The heart and vascular system are the earliest organs to form during embryonic development due to the tissue or organ's need for oxygen and nutrients and its reliance on the clearance of metabolites. Physiological angiogenesis occurs only in the reproductive system and during wound healing, and is transient and tightly controlled. [0003] Angiogenesis is a complex process, mainly composed of 10 consecutiv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/185A61P35/00A61P19/02A61P29/00A61P27/02A61P17/06
Inventor 郭青龙杨岚尤启冬卢娜顾红燕齐琦
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap